Kevin Outterson

rdf:langString Kevin Outterson

rdf:langString Kevin Outterson

rdf:langString Kevin Outterson

rdf:langString Health Law, Intellectual Property Law, Antibiotic Resistance

rdf:langString Law professor

rdf:langString Kevin Outterson is a lawyer, a professor of law and the N. Neal Pike Scholar in Health and Disability Law at Boston University (2014–present). He is also the founding executive director and principal investigator of Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership that supports companies developing new antibiotics, diagnostics, vaccines and other products to address drug-resistant bacterial infections. CARB-X is funded by the United States, United Kingdom and German governments, Wellcome and the Bill & Melinda Gates Foundation. In 2022, CARB-X received a new commitment of funding from BARDA and Wellcome of up to $370 million. The G7 Health Ministers have cited CARB-X among the critical initiatives to support as the G7 governments renew their 2021 commitment to address the most dangerous drug-resistant infections. Outterson's research focuses primarily on the law and economics of antibiotic resistance–including push and pull incentives–health law, intellectual property, and global access to medicine. Outterson has testified before Congress, the World Health Organization (WHO), UK Parliamentary working groups, and for the District of Columbia, Massachusetts, Vermont, California and West Virginia state legislatures. He is co-director of the health law program at Boston University School of Law (2007–present) and associate fellow at the Royal Institute of International Affairs at Chatham House, London (2014–present). He served on the Board of the American Society of Law, Medicine & Ethics, and serves as faculty editor to the American Journal of Law & Medicine (2007–present). He is past editor-in-chief of the Journal of Law, Medicine & Ethics (2010–2016).